These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34433365)

  • 1. Comprehensive value assessments for new pediatric pneumococcal conjugate vaccines.
    Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
    J Med Econ; 2021; 24(1):1083-1086. PubMed ID: 34433365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.
    Hu T; Weiss T; Owusu-Edusei K; Petigara T
    J Med Econ; 2020 Dec; 23(12):1653-1660. PubMed ID: 33084447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
    Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
    J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
    Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.
    Mohanty S; Hu T; Yang G; Khan TK; Owusu-Edusei K; Sukarom I
    Hum Vaccin Immunother; 2022 Nov; 18(5):2046433. PubMed ID: 35420975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United States.
    Mohanty S; Tsai JH; Ning N; Martinez A; Verma RP; Heisen M; Weaver J; Feemster KA; Chun B; Weiss TW; Schmier JK
    Hum Vaccin Immunother; 2024 Dec; 20(1):2325745. PubMed ID: 38566496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen.
    Ryman J; Sachs JR; Banniettis N; Weiss T; Ahsman M; Yee KL; Weaver J
    Expert Rev Vaccines; 2024; 23(1):467-473. PubMed ID: 38546743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014-2018.
    Hu T; Song Y; Done N; Mohanty S; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Weiss T
    BMC Health Serv Res; 2023 Apr; 23(1):398. PubMed ID: 37098521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines.
    Pichichero M; Malley R; Kaur R; Zagursky R; Anderson P
    Expert Rev Vaccines; 2023; 22(1):118-138. PubMed ID: 36565291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value.
    Janssens E; Flamaing J; Vandermeulen C; Peetermans WE; Desmet S; De Munter P
    Acta Clin Belg; 2023 Feb; 78(1):78-86. PubMed ID: 35171752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
    Link-Gelles R; Taylor T; Moore MR;
    Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
    Shirley M
    Drugs; 2022 Jun; 82(9):989-999. PubMed ID: 35793027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.